6-K ·Filed Mar 26, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001575872-26-000166
Notable filing: 6-K
Actionable Insight • Neutral

No immediate trading implications. Monitor for any pattern of ESOP exercises which could indicate employee sentiment, but this isolated event is immaterial to share value.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
RDY ▲ +1.89% at T+60d
NEUTRAL call ✓ call won +1.89% · α vs SPY -12.06% · entry $13.77 → $14.03
Entry anchored
Mar 25, 03:59 PM ET
via exchange tick
T+1d
-2.11%
call -2.11% · α -0.43%
$13.48
settled 6mo ago
T+5d
-3.27%
call -3.27% · α -4.90%
$13.32
settled 6mo ago
T+20d
-0.73%
call -0.73% · α -11.39%
$13.67
settled 5mo ago
T+60d
+1.89%
call +1.89% · α -12.06%
$14.03
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Dr. Reddy's Laboratories issued 3,675 equity shares on March 26, 2026, following the exercise of stock options under its 2007 ESOP scheme. The shares were allotted at par value of Re.1 each, with 3,100 shares issued at an exercise price of Rs. 735.80 each.

Key Facts

  • Company allotted 3,675 fully paid equity shares of Re.1 each on March 26, 2026
  • Shares were issued pursuant to the Dr. Reddy's Employees ADR Stock Options Scheme, 2007
  • 575 shares issued at Re.1 each, 3,100 shares issued at Rs. 735.80 each
  • Total issued share capital increased to 83,46,57,970 shares
  • Filing made under SEBI Listing Obligations & Disclosure Requirements Regulations, 2015

Financial Impact

Minimal financial impact - issuance of only 3,675 shares represents less than 0.005% of total outstanding shares

share_countequity_capital

Risk Factors

  • Minimal dilution effect from new share issuance
  • Potential perception of insider selling if option holders immediately sell shares

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000166
Document: 0001575872-26-000166-index.html0001575872-26-000166
Document: 0001575872-26-000166.txt0001575872-26-000166
51 reports for RDY
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +23.28%Jun 26, 2026
Filters
Rows
Reports for RDY — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
NEUTRAL ★ 3/10
$11.91 $11.55▼ −3.02%▼ −2.56%$12.25 (+2.85%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 5/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 2/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$12.22 $12.16▼ −0.49%▼ −1.15%$12.25 (+0.25%)
Aug 17, 2026
6w ago
6-K
MIXED ★ 5/10
$12.11 $12.15▲ +0.33%▲ +1.01%$12.25 (+1.16%)
Aug 13, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$12.42 $12.27▼ −1.21%▼ −1.01%$12.25 (−1.37%)
Aug 10, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$12.15 $12.45▲ +2.47%▲ +2.79%$12.25 (+0.82%)
Aug 3, 2026
8w ago
6-K
BULLISH ★ 6/10
$12.07 $12.10▲ +0.25%▼ −1.55%$12.25 (+1.49%)
Jul 29, 2026
9w ago
6-K
NEUTRAL ★ 4/10
$11.76 $11.83▲ +0.60%▼ −1.08%$12.25 (+4.17%)
Jul 23, 2026
10w ago
6-K
NEUTRAL ★ 2/10
$11.80 $11.79▼ −0.08%▼ −0.19%$12.25 (+3.81%)
Showing 10 of 51

US Market Status

Market Closed — Opens Mon (65h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access